Lorlatinib

Evidence Level: L5

Predicted Indications: 9

Lorlatinib

Pharmacist Assessment Report

Lorlatinib: From ALK-Positive Non-Small Cell Lung Cancer to Fibromatosis, Gingival

One-Sentence Summary

Lorlatinib is a third-generation ALK/ROS1 tyrosine kinase inhibitor, originally used to treat non-small cell lung cancer (NSCLC). The TxGNN model (deep learning) ranks gingival fibromatosis as its top predicted new indication (score 0.9981), but no clinical trials and no publications support this prediction, so it is a model-only signal. The strongest evidence found for other top-ranked candidates in this list actually concerns the already approved NSCLC use, or ALK-driven neuroblastoma, not the predicted diseases themselves.

Quick Overview

Item	Content
Original Indication	Non-small cell lung carcinoma / lung cancer
Predicted New Indication	Fibromatosis, gingival
TxGNN Prediction Score	0.9981
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (2 of 2) – CDSCO approval status is not included in this data
Number of Listed Products	2 (valid: 2)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, lorlatinib is a brain-penetrant, third-generation ALK/ROS1 kinase inhibitor. Its efficacy in ALK-positive NSCLC has been established in the Phase 3 CROWN trial, but there is no established link between ALK/ROS1 inhibition and gingival fibromatosis.

The prediction for gingival fibromatosis comes from the TxGNN model (deep learning) only, and its score may reflect similarities the model learned between related diseases, not biological evidence. There are no trials, no publications, and no plausible mechanistic rationale, so it should be treated as a hypothesis-generating signal at best.

Other highly ranked predictions show the same weakness:

Fibroma of lung, hamartoma of lung, pulmonary sulcus neoplasm, lung benign neoplasm: these have no direct evidence. The literature attached to lung benign neoplasm is about malignant ALK-positive NSCLC, the already approved indication, and does not transfer to benign tumours. This appears to be a disease-ontology artifact.
Lung hilum carcinoma: a single 2023 case report described a pathological complete response after neoadjuvant lorlatinib in ALK-positive lung cancer. This falls under the existing NSCLC indication, not a new one.
Lung germ cell tumor: the literature is about ALK-driven neuroblastoma (including a Phase 1 trial), not lung germ cell tumors. It supports ALK-inhibition biology in ALK-aberrant tumours, and ALK-driven neuroblastoma may merit separate assessment.
Genetic disorders (VCP-related inclusion body myopathy, junctional epidermolysis bullosa, leukomelanoderma syndrome): no plausible link to ALK/ROS1 inhibition. The literature retrieved for the last one concerns lorlatinib adverse effects, not efficacy.

Clinical Trial Evidence

Currently no related clinical trials registered for gingival fibromatosis. No clinical trials were found for any of the top 10 predicted indications either. Related trial evidence appears only in the publications below (for example, the Phase 3 CROWN trial in NSCLC and a Phase 1 neuroblastoma trial, NCT03107988).

Literature Evidence

No publications were found for the top predicted indication, gingival fibromatosis. The table below lists the most relevant publications retrieved for the other predicted indications; they relate to the approved NSCLC indication or to ALK-driven neuroblastoma, not to the predicted diseases.

PMID	Year	Type	Journal	Key Findings
33207094	2020	RCT (Phase 3 CROWN)	N Engl J Med	First-line lorlatinib vs crizotinib in advanced ALK-positive NSCLC (approved indication)
38819031	2024	RCT (5-year follow-up)	J Clin Oncol	Long-term progression-free survival and intracranial benefit of lorlatinib vs crizotinib
42217582	2026	RCT (7-year update)	Ann Oncol	Continued long-term PFS benefit in first-line ALK-positive NSCLC
36535300	2023	RCT (CROWN analysis)	Lancet Respir Med	Updated 3-year efficacy and intracranial activity
39368244	2024	Network meta-analysis	Lung Cancer	Lorlatinib compared with other ALK TKIs in first-line ALK-positive NSCLC
37012551	2023	Phase 1 trial	Nat Med	Lorlatinib with or without chemotherapy in ALK-driven relapsed/refractory neuroblastoma showed safety and activity
37147298	2023	Cohort / ctDNA study	Nat Commun	ctDNA reveals lorlatinib resistance mechanisms in ALK-driven neuroblastoma
37934724	2023	Case report	Am J Case Rep	Pathological complete response after neoadjuvant lorlatinib in advanced ALK-positive lung cancer
40287137	2025	Pharmacovigilance study	Endocr Pract	FAERS analysis of lorlatinib-associated metabolic effects (hypercholesterolemia, hypertriglyceridemia, weight gain)
40551396	2025	Case report	Pediatr Blood Cancer	Pulmonary toxicity with concurrent lorlatinib and anti-GD2 antibody in neuroblastoma

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
129170	Lorbriqua 25mg Tablet	Box of 30 tablets	Not stated in the data compiled
129171	Lorbriqua 100mg Tablet	Box of 30 tablets	Not stated in the data compiled

Both licences are valid single-ingredient oral products from Pfizer Ltd.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (ALK/ROS1 tyrosine kinase inhibitor)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Lipid profile (hypercholesterolaemia and hypertriglyceridaemia are reported), plus routine blood counts and liver and renal function; pulmonary symptoms and CNS effects (see the adverse-event management publications)
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Drug Interactions: 461 interactions are recorded. Major-level interactions include dexamethasone and clarithromycin. Moderate-level interactions include hydrocortisone, triamcinolone, betamethasone, bupropion, aprepitant, morphine, cimetidine, and several antidiabetic agents (dapagliflozin, empagliflozin, saxagliptin, linagliptin, glimepiride, chlorpropamide).
Adverse-event signals from the literature (not label text): hyperlipidaemia and dyslipidaemia, acute respiratory distress syndrome (case report), Sweet syndrome (case report), and pulmonary toxicity when combined with anti-GD2 antibody therapy.

Please refer to the package insert for full warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction, gingival fibromatosis, is supported only by a score from the TxGNN model (deep learning), which may reflect similarities the model learned between related diseases, not biological evidence. There are no trials, no publications, and no plausible ALK/ROS1 mechanism. The evidence level is L5. Strong evidence exists only for the already approved NSCLC use, and it cannot be carried over to the predicted diseases.

To proceed, the following is needed:

Package insert warnings and contraindications (a blocking data gap for safety screening)
Mechanism of action data (a high-priority gap)
A biological rationale linking ALK/ROS1 signalling to gingival fibromatosis, supported by preclinical data
Separate assessment of ALK-driven neuroblastoma as a distinct candidate indication, given the Phase 1 evidence
Evaluation of route compatibility and the similarity of the predicted indication to the original one
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.